- Report
- August 2025
- 124 Pages
Global
From €3520EUR$3,999USD£3,046GBP
- Report
- January 2026
- 181 Pages
Global
From €3121EUR$3,545USD£2,700GBP
€3468EUR$3,939USD£3,000GBP
- Report
- February 2026
- 250 Pages
Global
From €3953EUR$4,490USD£3,419GBP
- Report
- February 2026
- 250 Pages
Global
From €3953EUR$4,490USD£3,419GBP
- Report
- December 2025
- 142 Pages
Global
From €4270EUR$4,850USD£3,694GBP
- Report
- April 2025
- 200 Pages
Global
From €2192EUR$2,490USD£1,896GBP
- Report
- September 2023
- 180 Pages
Global
From €5238EUR$5,950USD£4,531GBP
- Report
- June 2024
- 200 Pages
Global
From €6999EUR$7,950USD£6,054GBP
- Report
- June 2022
- 320 Pages
Global
From €12237EUR$13,900USD£10,586GBP
- Report
- January 2024
- 206 Pages
Global
From €3917EUR$4,450USD£3,389GBP
- Report
- June 2023
- 280 Pages
Global
From €2201EUR$2,500USD£1,904GBP

Choroidal Neovascularization (CNV) is a condition in which abnormal blood vessels grow beneath the retina in the eye. It is a major cause of vision loss in age-related macular degeneration (AMD). Optical treatments for CNV include laser photocoagulation, photodynamic therapy, and anti-VEGF injections. Laser photocoagulation is used to destroy the abnormal blood vessels and prevent further vision loss. Photodynamic therapy uses a light-activated drug to destroy the abnormal vessels. Anti-VEGF injections are used to block the growth of new vessels and reduce fluid leakage.
The CNV market is highly competitive, with a number of companies offering treatments and products. These include Novartis, Regeneron, Allergan, Roche, Bayer, and Santen Pharmaceuticals. Show Less Read more